Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The State Food and Drug Administration of China has approved GNI's investigational new drug application for the clinical development of the biopharmaceutical company's drug candidate for the treatment of liver fibrosis.
Subscribe to our email newsletter
GNI’s China-based affiliate, Shanghai Genomics, is in the process of preparing its Phase I trial for the drug, F351.
Jun Wu‚ chief scientific officer of GNI, and Shanghai Genomics, said: “We have shown that F351 specifically inhibits over-production of collagen by liver fibroblasts following inflammatory insults. The possibility to intervene in such inflammatory process has enormous relevance to the treatment of fibrotic diseases in humans.”